This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

Switching to and from ELIQUIS® (apixaban)

When switching between anticoagulant regimens, please ensure you have considered the individual patient’s clinical profile as well as drug characteristics that may influence dosing. Please see the relevant SmPC for more information.

Switching to ELIQUIS

Switching from ELIQUIS to warfarin

Please refer to the ELIQUIS Summary of Product Characteristics (SmPC) for more information.1

We have developed a checklist to support healthcare professionals when prescribing ELIQUIS for stroke prevention in patients with NVAF switching from warfarin.

To download and print the checklist, click here.


BD = Twice Daily   DOAC = Direct-acting Oral Anticoagulant   INR = International Normalised Ratio   NVAF = Non-Valvular Atrial Fibrillation   SmPC = Summary of Product Characteristics   UFH = Unfractionated Heparin


  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at
  2. Steffel J et al. Europace 2021; doi:10.1093/europace/euab065.